Welcome to our dedicated page for Kalaris Therapeutics SEC filings (Ticker: KLRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kalaris Therapeutics filings document formal disclosures for a Nasdaq-listed clinical-stage biopharmaceutical company developing retinal-disease therapeutics. The record includes 8-K reports on operating and financial results, Regulation FD clinical presentations for TH103, material-event disclosures, capital-structure matters, and executive officer changes.
Proxy materials describe annual meeting and shareholder voting matters, while security disclosures identify Kalaris common stock under the KLRS ticker. Clinical disclosures focus on TH103 safety, tolerability, pharmacokinetics, early efficacy information, manufacturing updates, and the company's retinal-disease development plans.
Kalaris Therapeutics, Inc. registers for resale up to 5,000,000 shares of its common stock, consisting of 4,200,000 outstanding shares and 800,000 shares issuable upon exercise of pre-funded warrants. The prospectus covers resales by the selling stockholders; the company will not receive proceeds from resales, although it would receive cash if pre-funded warrants are exercised at an exercise price of $0.0001 per share. The shares were issued in a private placement that generated approximately $50.0 million in gross proceeds at a price of $10.00 per share (and pre-funded warrants at $9.9999), and the registration statement was filed to satisfy registration rights. Shares outstanding were 22,928,303 as of February 28, 2026. The prospectus permits sales on Nasdaq or other methods described under "Plan of Distribution," and notes a Beneficial Ownership Limitation (default 4.99%, adjustable up to 19.99% with notice).
Kalaris Therapeutics Chief Accounting Officer Brett R. Hagen reported an open-market sale of 1,915 shares of common stock at $6.72 per share, leaving no directly held common shares after the transaction. On the prior day, he received a grant of stock options for 60,800 shares of common stock at an exercise price of $6.81 per share, expiring on March 18, 2036. According to the grant terms, 25% of the underlying shares vest on March 19, 2027, with the remainder vesting in equal monthly installments thereafter, subject to continuous service. A footnote clarifies that a previous filing overstated his beneficial ownership by 10 shares, from 1,925 to 1,915, and this has now been corrected.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting proposed sales tied to multiple parcels of restricted Common stock that vest under a registered plan. The notice lists individual vesting dates and share quantities, including 1,098 shares vesting on 03/18/2025 and smaller tranches across 2024–2025.
The filing enumerates vesting events labeled "Restricted stock vesting under a registered plan" with specific dates and share counts; these entries reflect planned dispositions associated with service‑based vesting rather than an open‑market transaction detail or aggregate registered amount.
Kalaris Therapeutics director and officer Andrew Oxtoby received a stock option grant covering 222,000 shares of Common Stock. The option was granted as a compensation award with an exercise price of $6.8100 per share and expires on March 18, 2036.
The shares underlying the option vest over four years, with 25% vesting on March 19, 2027 and the remaining 75% vesting in equal monthly installments thereafter, subject to continuous service. Following this grant, Oxtoby holds 222,000 derivative securities directly.
Kalaris Therapeutics, Inc. reported that Chief Financial Officer Matthew Gall received a grant of stock options for 95,000 shares of common stock. The options carry an exercise price of $6.81 per share, expire on March 18, 2036, and vest over four years starting March 19, 2027.
Kalaris Therapeutics, Inc. reported that Chief Medical Officer Matthew Feinsod received a grant of stock options covering 135,000 shares of common stock. The options have an exercise price of $6.81 per share and expire on March 18, 2036.
According to the vesting terms, 25% of the underlying shares are scheduled to vest on March 19, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continuous service. After this grant, Feinsod holds options for 135,000 shares directly.
Kalaris Therapeutics, Inc., formerly AlloVir, has transformed into a clinical-stage biopharmaceutical company focused on prevalent retinal diseases after completing a merger with Legacy Kalaris on March 18, 2025. The company’s strategy centers on TH103, a novel anti‑VEGF fusion protein engineered for extended intraocular retention via high‑affinity binding to VEGF and heparan sulfate proteoglycans.
Initial Phase 1a data in neovascular age‑related macular degeneration showed a mean 10‑letter gain in visual acuity and strong fluid resolution after a single dose, with TH103 generally well tolerated aside from some intraocular inflammation that the company is addressing through manufacturing process refinements to lower host cell proteins. A Phase 1b/2 multiple‑dose study in nAMD is ongoing, with preliminary data expected in the first half of 2027, and Kalaris plans potential Phase 3 trials by year‑end 2027 plus indication expansion into diabetic eye disease, retinal vein occlusion and retinopathy of prematurity. The company reports an aggregate market value of non‑affiliate equity of $12.6 million as of June 30, 2025 and 22,928,303 common shares outstanding as of March 10, 2026, and highlights typical early‑stage biotech risks, including continued losses, substantial funding needs, heavy dependence on TH103 and Nasdaq “controlled company” status due to principal stockholder Samsara BioCapital.
Kalaris Therapeutics reported a narrower full-year 2025 net loss of $43.4 million, improved from $69.2 million in 2024, as it advanced its lead retinal drug candidate TH103.
Cash, cash equivalents and marketable securities rose to $118.0 million as of December 31, 2025, from $1.6 million a year earlier, driven by its March 2025 merger with AlloVir and an oversubscribed $50.0 million private placement in December. The company expects this cash to fund operations into the fourth quarter of 2027.
Research and development expenses fell to $30.8 million from $45.0 million, largely reflecting a prior-year royalty obligation, while general and administrative costs increased to $15.4 million from $6.7 million as Kalaris scaled public-company infrastructure. Shares outstanding were 22,902,418 as of December 31, 2025.
Clinically, Kalaris reported positive initial Phase 1a single ascending dose data in neovascular age-related macular degeneration, noting TH103 was generally well tolerated with no dose-limiting toxicities or treatment-related serious adverse events. An ongoing Phase 1b/2 multiple ascending dose trial began enrolling in 2025, with preliminary data expected in the first half of 2027, and the company intends to start Phase 3 trials by year-end 2027.
Kalaris Therapeutics, Inc. furnished an updated corporate presentation outlining development plans and early data for its lead retinal therapy candidate, TH103. The company highlights TH103 as an engineered anti-VEGF fusion protein designed for extended intraocular retention and enhanced VEGF inhibition in neovascular retinal diseases such as nAMD.
Initial Phase 1a single-ascending dose data showed rapid, robust improvements in visual acuity and retinal fluid measures at one month, with TH103 generally well tolerated and no dose-limiting toxicities reported. An ongoing Phase 1b/2 multi-dose trial in nAMD is underway, with preliminary data expected in the first half of 2027 and potential Phase 3 initiation planned by year-end 2027, subject to results.
The presentation also notes a $50 million oversubscribed private placement completed in December 2025 and states that the company’s cash runway is expected to fund operations into the fourth quarter of 2027. Kalaris emphasizes continued manufacturing process refinements aimed at reducing host cell protein levels and outlines intellectual property protection for TH103 compositions and methods of use, with U.S. exclusivity expected into the early 2040s.
Kalaris Therapeutics, Inc. reported an insider-related block trade in its common stock involving affiliated investment funds. Samsara Opportunity Fund, L.P., an entity associated with director and 10% owner Srinivas Akkaraju, made an open-market style, privately negotiated purchase of 479,847 common shares at $10.42 per share from Samsara BioCapital, L.P.
Following this transaction, Samsara Opportunity Fund held 1,979,847 Kalaris Therapeutics shares, while Samsara BioCapital, L.P. held 10,968,234 shares. The filing notes that Akkaraju and related general partner entities may be deemed beneficial owners but disclaim beneficial ownership beyond their pecuniary interests, and one footnote states the transfer from Samsara BioCapital, L.P. did not change Akkaraju’s overall beneficial ownership.